Dr Massimo Cristofanilli, MD Joins Datar Cancer Genetics as Strategic Advisor
A Visionary Leader in Cancer Research
Dr. Cristofanilli has an esteemed career with over 400 scientific publications on cancer biomarkers, liquid biopsy, and targeted therapies. He is a past President of the International Society of Liquid Biopsy (ISLB).
'It is my pleasure to take up this role,' said Dr. Cristofanilli. 'I look forward to collaborating with the DCG team to drive the development of next-generation cancer diagnostic tests that will form the backbone of transformative technologies to detect and treat cancer.'
Enhancing Cancer Diagnostics and Precision Medicine
This collaboration will strengthen DCG's leadership in molecular and functional tumor profiling and liquid biopsies, particularly in circulating tumor cells (CTCs). Dr. Cristofanilli will work with DCG's research teams to expand biomarker-driven innovations for challenging cancers.
'Dr. Cristofanilli's expertise is invaluable to DCG's vision of pushing onco-diagnostics forward,' said Dr. Darshana Patil, MD, Senior Director – Global Strategy and Medical Affairs, DCG. 'His leadership will help refine strategies for next-generation, safer, and more reliable technologies,' added Mr. Rajan Datar, Chairman and Managing Director, DCG.
About Datar Cancer Genetics
Datar Cancer Genetics is a global oncology research company developing non-invasive technologies for improved cancer detection, treatment, and management. The Company's state-of-the-art cancer research centres in the UK, and India are accredited by the relevant certification such as ISO, UKAS, ILAC, CAP and CLIA. The Company serves cancer patients and suspected cases in the UK, European Union, United States, GCC, and India.
About Dr. Massimo Cristofanilli
Dr. Cristofanilli is a board-certified medical oncologist specializing in molecular diagnostics, liquid biopsy, and drug development, with a focus on metastatic breast cancer. He is Director of Breast Medical Oncology and Scientific Director of the Englander Institute for Precision Medicine at Weill Cornell Medicine. A pioneer in Inflammatory Breast Cancer (IBC), he founded the IBC International Consortium and has co-authored over 400 peer-reviewed publications.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
a day ago
- New York Times
MLB commissioner Rob Manfred downplays confrontation with Phillies superstar Bryce Harper
CHICAGO — Amid rising labor tensions, Major League Baseball commissioner Rob Manfred downplayed a recent confrontation with Philadelphia Phillies superstar Bryce Harper, who delivered this direct message during the league's presentation to the team: 'If you're talking about a salary cap you can get the f— out.' Advertisement 'I don't talk about those player meetings,' Manfred said Friday at Wrigley Field. 'Let me say this: I think more has been made out of this than needs to be made out of it. Bryce expressed his views at the end of the meeting. We shook hands and went our separate ways. Not all that significant.' Manfred, who has been touring clubhouses to talk with players about the sport's economics, visited the Friendly Confines to announce formally that the Chicago Cubs will host the 2027 All-Star Game. With the sport's current labor deal set to expire after the 2026 season, Manfred faced questions about contingency plans and the possibility that a protracted lockout could cancel that Midsummer Classic. 'It is natural that when we get to the end of a collective bargaining agreement (some) people have trepidation about what's going to happen,' Manfred said. 'I'm optimistic that we'll find a way to make a deal.' Harper's frustrations, though, seemingly illustrated the divide between the MLB Players Association and Manfred, a deeply experienced labor lawyer who's now in his third term as commissioner. 'I came in-house in 1998,' Manfred said. 'We haven't had a work stoppage that affected a season since that time. Three of those deals, I was the chief negotiator. Two of them, I was the commissioner. That's a pretty good record. And, you know, I think we can do it again.' Harper is in the middle of a 13-year, $330 million contract, a massive investment that helped revitalize the Philadelphia franchise. It is also the kind of long-term megadeal that would be even harder for a star player to secure under a salary cap. One of the game's most recognizable players getting in the face of its commissioner is, at the very least, unusual. 'It was an individual picking a particular way to express himself,' Manfred said. 'And I don't think you need to make more out of that than that.'
Business Wire
a day ago
- Business Wire
A-CAP Announces Strategic Financing
NEW YORK--(BUSINESS WIRE)--Advantage Capital Holdings, LLC ('A-CAP' or 'the Company'), a New York-based insurance and financial services company with over $16 billion in assets, today announced that one of its wholly owned subsidiaries has completed a strategic capital transaction with affiliates of BDT & MSD Partners, LLC ('BDT & MSD'). The investment is structured as a credit facility with features that provide flexibility to support the company's growth and long-term objectives. 'We are excited to partner with a prestigious firm that has a track record like BDT & MSD. Their continued support of founder-owned businesses was highly attractive to us when deciding on a capital partner' said Kenneth King, Chairman and CEO of A-CAP. 'This transaction will not only strengthen A-CAP's financial position, but also fuel the next stage of growth for A-CAP's diversified financial services platform.' Moelis & Company LLC acted as exclusive financial advisor to A-CAP. Cadwalader, Wickersham & Taft LLP served as legal advisor to A-CAP and Latham & Watkins LLP served as legal advisor to BDT & MSD. About A-CAP A-CAP is a holding company owning multiple insurance and financial businesses on its unique and synergistic platform. These businesses include primary insurance carriers, an SEC registered investment adviser, reinsurance vehicles, and marketing organizations. With broad knowledge across the insurance and investment sectors, A-CAP's management team has diverse experience and provides comprehensive services to policyholders, insurance company clients and capital partners. Launched in 2013, A-CAP is a privately held company with offices located in New York, Charleston, Miami, and Salt Lake City. For more information, visit
Yahoo
a day ago
- Yahoo
Xtalks Announces its Life Science Webinar Calendar for August 2025
Upcoming free, educational webinars from Xtalks will feature topics on cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, healthcare, laboratory technology, medical device, patient recruitment & retention, pharma manufacturing & supply chain and preclinical. TORONTO, Aug. 1, 2025 /PRNewswire/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field! Visit to see our upcoming webinars: CELL AND GENE THERAPYAugust 22 - How Cell-Free mRNA Templates Support Faster Research with High-Quality and Quick Turnaround CLINICAL TRIALSAugust 7 - Improving Clinical Tech Adoption: Site-Centric ApproachesAugust 13 - Accelerating Clinical Research with Master Protocols: Challenges and Benefits to Complex Trial DesignsAugust 14 - Designing Innovative Trials: Navigating Dose Optimization in Oncology CombinationsAugust 15 - AI in Clinical Trials: Early Use Cases and Innovations COMMERCIALIZATION & HEORAugust 19 - 5 Critical Questions to Ask Before Applying AI to Real-World Data DRUG DISCOVERY & DEVELOPMENTAugust 7 - Oral Dosage Innovation for Pediatric Drug DeliveryAugust 7 - Cancer Drug Discovery: A Synthetic Lethality Approach Using Integrated PlatformsAugust 12 - Radiotracers and ADC Targeting: Scientific Insights for In Vivo Validation and Clinical TransitionAugust 13 - AI in Drug Discovery & Development: Hype, Reality and What Comes NextAugust 21 - Dose Escalation: Optimizing Cohort Management in Early-Phase DevelopmentAugust 26 - AI in Bioprocessing Today — Accelerate. Predict. Deliver. HEALTHCAREAugust 20 - Beyond Diagnosis: The Real-World Impact of AVISE Testing on Lupus, Rheumatoid Arthritis, and Autoimmune Disease Care LABORATORY TECHNOLOGYAugust 6 - Precision Matters: The Critical Role of Accurate Liquid Handling in the Lab MEDICAL DEVICEAugust 25 - Transforming Medical Imaging with AI: Open Tools, Faster Insights PATIENT RECRUITMENT & RETENTIONAugust 20 - Transforming Patient Recruitment: AI and Digital Strategies to Engage the Unreachable 95%August 27 - Enhancing Patient Recruitment in Clinical Research: A Personalized and Engaged Journey PHARMA MANUFACTURING & SUPPLY CHAINAugust 14 - Biofermentation Success Through pH and DO Management PRECLINICALAugust 26 - Advanced In Vivo Efficacy Models for Preclinical Success ABOUT XTALKS Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit Contact:Ayesha RashidXtalks ( Tel: +1 (416) 977-6555 x371Email: arashid@ View original content to download multimedia: SOURCE Xtalks Inicia sesión para acceder a tu cartera de valores
